P/B
33,5
Eli Lilly and
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
$1.3T
Market Cap • 11/10/2026
1901
(125 years)
Founded
1970
(56 years ago)
IPO
NYSE
Listing Exchange
United States
Country
S&P500 Participant
Index Composite • 2026
Valuation
P/S
15,6
P/EBITDA
36,4
P/OCF
44
P/FCF
68,5
P/E
46,5
BVPS
42,8
EPS
30,8
Market Cap
Market Cap
1,3T
EV
1,4T
EV/Revenue
16,1
EV/EBITDA
37,6
EV/EBIT
39,9
Payout
Dividend Per Share
6,7
Dividend Yield
0,5%
Buyback Yield
0,4%
Total Yield
0,9%
Dividend Yield 5Y
0,6%
Payout
21,7%
Retained Earnings
38B
Profitability
Gross Margin
83,6%
EBITDA Margin
42,9%
EBIT Margin
40,3%
Net Margin
31,9%
D&A/EBITDA
0%
R&D/Revenue
27,1%
Capex/Revenue
12,7%
Capex/D&A
505,2%
Capex/OCF
35,8%
SBC/OCF
2,3%
% PPE
21,7%
% Goodwill
6,7%
ROE
86%
ROIC
33,5%
Growth
CAGR Revenue 5Y
25,5%
CAGR Op. Income 5Y
39,8%
CAGR Net Income 5Y
35,8%
CAGR EPS 5Y
36,3%
CAGR OCF 5Y
34,7%
Leverage
N.D./EBITDA
1,2
Debt/Equity
0%
Current Ratio
1,4
Quick Ratio
0,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!